Published in Nat Med on January 01, 2001
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol (2009) 4.66
In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A (2003) 4.18
Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med (2003) 3.76
Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med (2002) 3.20
Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant (2007) 2.61
OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52
IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol (2009) 1.91
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci U S A (2002) 1.69
Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest (2008) 1.66
An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. J Exp Med (2007) 1.59
Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol (2010) 1.58
The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer (2003) 1.48
Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase. Immunol Cell Biol (2011) 1.45
Regulation of innate CD8+ T-cell activation mediated by cytokines. Proc Natl Acad Sci U S A (2012) 1.38
Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci U S A (2007) 1.35
Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother (2009) 1.32
CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J Clin Invest (2009) 1.29
Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood (2010) 1.21
Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med (2006) 1.21
Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines. J Immunol (2006) 1.16
Regulation of CD4+ T-cell contraction during pathogen challenge. Immunol Rev (2010) 1.14
Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses. Front Immunol (2012) 1.14
Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest (2002) 1.12
Design principles of cell circuits with paradoxical components. Proc Natl Acad Sci U S A (2012) 1.11
Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res (2014) 1.08
HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci U S A (2002) 1.04
An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J Immunol (2001) 1.03
IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J Clin Invest (2002) 1.03
Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc Natl Acad Sci U S A (2002) 0.99
Prolonged exposure of naïve CD8+ T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length. Immunology (2006) 0.99
T cell-specific notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells. J Immunol (2013) 0.96
Routes to transplant tolerance versus rejection; the role of cytokines. Immunity (2004) 0.95
Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice. J Exp Med (2003) 0.94
Memory CD8 T cells specific for plasmodia liver-stage antigens maintain protracted protection against malaria. Front Immunol (2012) 0.94
T regulatory cells and transplantation tolerance. Transplant Rev (Orlando) (2010) 0.90
Pleiotropic effects of negative energy balance in the postpartum dairy cow on splenic gene expression: repercussions for innate and adaptive immunity. Physiol Genomics (2009) 0.89
Chronic Leishmania donovani infection promotes bystander CD8+-T-cell expansion and heterologous immunity. Infect Immun (2005) 0.87
An antagonist mutant IL-15/Fc promotes transplant tolerance. Transplantation (2006) 0.87
CAR-T Cell Therapy for Lymphoma. Annu Rev Med (2015) 0.86
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85
IL-2 receptor gamma chain cytokines differentially regulate human CD8+CD127+ and CD8+CD127- T cell division and susceptibility to apoptosis. Int Immunol (2008) 0.85
CD8(+) T cells resistant to costimulatory blockade are controlled by an antagonist interleukin-15/Fc protein. Transplantation (2006) 0.84
Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans. J Immunol (2008) 0.83
T-cell activation, proliferation and apoptosis in primary Listeria monocytogenes infection. Immunology (2002) 0.81
A Mouse Model of Latent Tuberculosis Infection to Study Intervention Strategies to Prevent Reactivation. PLoS One (2016) 0.81
Intracellular insulin-like growth factor-1 induces Bcl-2 expression in airway epithelial cells. J Immunol (2012) 0.81
Prolonged survival of allogeneic islets in cynomolgus monkeys after short-term triple therapy. Am J Transplant (2012) 0.81
Retracted Desmoglein 3-specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor Foxp3. Immunology (2009) 0.80
Alloreactive CD8 T cells rescued from apoptosis during co-stimulation blockade by Toll-like receptor stimulation remain susceptible to Fas-induced cell death. Immunology (2013) 0.80
Defective function of Fas in T cells from paediatric patients with autoimmune thyroid diseases. Clin Exp Immunol (2003) 0.79
Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice. Clin Exp Immunol (2005) 0.78
Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors. J Immunother (2008) 0.78
Interleukin-7 and interleukin-15 for cancer. J Cancer (2014) 0.78
2006 Homer W. Smith Lecture: taming T cells. J Am Soc Nephrol (2007) 0.77
Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates. J Heart Lung Transplant (2012) 0.77
Monoclonal regulatory T cells provide insights into T cell suppression. Sci Rep (2016) 0.77
Rapid down-regulation of γc on T cells in early SIV infection correlates with impairment of T-cell function. FASEB J (2012) 0.76
Alloreactive CD8 T-cell primed/memory responses and accelerated graft rejection in B-cell-deficient sensitized mice. Transplantation (2011) 0.76
Tolerance--is it worth it? Cold Spring Harb Perspect Med (2014) 0.75
IL-15 enhances the antitumor effect of human antigen-specific CD8(+) T cells by cellular senescence delay. Oncoimmunology (2016) 0.75
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol (1984) 5.51
Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol (1993) 5.16
Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex. Proc Natl Acad Sci U S A (1983) 4.83
Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 4.05
Renal transplantation. N Engl J Med (1994) 3.33
T cell-activating properties of an anti-Thy-1 monoclonal antibody. Possible analogy to OKT3/Leu-4. J Exp Med (1984) 3.26
B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity (1997) 3.22
Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med (1999) 3.17
Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med (1983) 2.94
Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med (1999) 2.74
Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol (1986) 2.68
Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant (2007) 2.61
The murine IL 2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. J Immunol (1984) 2.60
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci (1992) 2.47
Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia (2011) 2.43
De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant (2011) 2.28
Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol (1984) 2.26
The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. J Immunol (1985) 2.14
Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med (1984) 2.03
Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc Natl Acad Sci U S A (1972) 2.01
Nucleotide sequence and expression of a mouse interleukin 2 receptor cDNA. J Immunol (1985) 2.00
The modulating influence of cyclic nucleotides upon lymphocyte-mediated cytotoxicity. J Exp Med (1973) 1.92
What does it mean to be a donor offspring? The identity experiences of adults conceived by donor insemination and the implications for counselling and therapy. Hum Reprod (2000) 1.90
Role of Ly-6 in lymphocyte activation. II. Induction of T cell activation by monoclonal anti-Ly-6 antibodies. J Exp Med (1986) 1.87
Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med (1975) 1.82
MRI changes in psoriatic dactylitis--extent of pathology, relationship to tenderness and correlation with clinical indices. Rheumatology (Oxford) (2008) 1.80
Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol (1987) 1.73
Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I. J Exp Med (1983) 1.71
A multistate outbreak of oyster-associated gastroenteritis: implications for interstate tracing of contaminated shellfish. J Infect Dis (1995) 1.69
Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant (2007) 1.64
Effect of bran particle size on stool weight. Gut (1978) 1.63
A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-lpr mice. J Immunol (1985) 1.58
Both L3T4+ and Lyt-2+ helper T cells initiate cytotoxic T lymphocyte responses against allogenic major histocompatibility antigens but not against trinitrophenyl-modified self. J Exp Med (1985) 1.57
Rapamycin induces transforming growth factor-beta production by lymphocytes. Transplantation (2000) 1.56
Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant (2010) 1.55
Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. Colorectal Dis (2006) 1.52
T cell death and transplantation tolerance. Immunity (2001) 1.51
Both interleukin 2 and a second T cell-derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis. J Exp Med (1984) 1.51
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A (2000) 1.50
Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A (1997) 1.48
CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol (1997) 1.47
Factors contributing to the declining mortality rate in renal transplantation. N Engl J Med (1978) 1.45
The murine IL 2 receptor. III. Cellular requirements for the induction of IL 2 receptor expression on T cell subpopulations. J Immunol (1985) 1.40
Interleukin-7 receptor alpha is essential for the development of gamma delta + T cells, but not natural killer cells. J Exp Med (1996) 1.36
Decreased expression of human class II antigens on monocytes from patients with acquired immune deficiency syndrome. Increased expression with interferon-gamma. J Clin Invest (1984) 1.36
Characterization of two novel Ly-6 genes. Protein sequence and potential structural similarity to alpha-bungarotoxin and other neurotoxins. J Immunol (1993) 1.35
The murine IL 2 receptor. II. Monoclonal anti-IL 2 receptor antibodies as specific inhibitors of T cell function in vitro. J Immunol (1984) 1.34
Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med (1985) 1.34
The role of nonclassical Fc receptor-associated, Ag-B antigens (Ia) in rat allograft enhancement. J Exp Med (1976) 1.33
Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J Immunol (1998) 1.32
Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol (1998) 1.32
Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol (1995) 1.29
Improved B cell typing for HLA-DR using nylon wool column enriched B lymphocyte preparations. Tissue Antigens (1979) 1.29
The murine interleukin 2 receptor. Irreversible cross-linking of radiolabeled interleukin 2 to high affinity interleukin 2 receptors reveals a noncovalently associated subunit. J Immunol (1987) 1.29
Characterization of two distinct primary T cell populations that secrete interleukin 2 upon recognition of class I or class II major histocompatibility antigens. J Exp Med (1986) 1.29
Cyclosporin A spares selectively lymphocytes with donor-specific suppressor characteristics. Transplantation (1981) 1.28
Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations. Am J Transplant (2009) 1.27
Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng (1987) 1.27
Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem (1990) 1.26
Interleukin-2 receptor regulates activation of phosphatidylinositol 3-kinase. J Biol Chem (1991) 1.26
Interleukin 2 upregulates expression of its receptor on a T cell clone. J Exp Med (1985) 1.25
Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. J Immunol (1996) 1.24
Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med (1988) 1.23
Role of protein and RNA synthesis in the development of insulin binding sites on activated thymus-derived lymphocytes. J Biol Chem (1979) 1.22
Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol (1994) 1.21
Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci U S A (1986) 1.21
Differential effect of cyclosporin A on the expression of T and B lymphocyte activation antigens. J Immunol (1984) 1.20
Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. Am J Transplant (2011) 1.20
Accessory cell requirement for activation antigen expression and cell cycle progression by human T lymphocytes. J Immunol (1984) 1.19
Heritable susceptibility for colitis in mice induced by IL-10 deficiency. Inflamm Bowel Dis (2000) 1.17
IL-2 knockout recipient mice reject islet cell allografts. J Immunol (1995) 1.17
Interleukin 2 receptors on cultured murine epidermal Langerhans cells. J Immunol (1986) 1.16
Evidence for additional subunits associated to the mouse interleukin 2 receptor p55/p75 complex. Proc Natl Acad Sci U S A (1990) 1.16
The proteasome regulates receptor-mediated endocytosis of interleukin-2. J Biol Chem (2001) 1.15
Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation (1998) 1.14
Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation (1998) 1.13
Cellular components of allograft rejection: identity, specificity, and cytotoxic function of cells infiltrating acutely rejecting allografts. J Immunol (1977) 1.12
Anti-interleukin 2 receptor antibody suppresses delayed-type hypersensitivity to foreign and syngeneic antigens. J Immunol (1986) 1.12
Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc Natl Acad Sci U S A (1988) 1.10
Rejected human renal allografts: recovery and characteristics of infiltrating cells and antibody. Transplantation (1979) 1.10
Late mortality and morbidity in recipients of long-term renal allografts. Transplantation (1982) 1.10
Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol (1994) 1.10
Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant (2008) 1.10
Emergence of insulin receptors upon alloimmune T cells in the rat. J Clin Invest (1977) 1.09
Identification of a membrane antigen that is distinct from the interleukin 2 receptor and that may be required for interleukin 2-driven proliferative responses. J Immunol (1983) 1.09
Insulin-induced augmentation of lymphocyte-mediated cytotoxicity. Science (1975) 1.08
Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. J Biol Chem (1990) 1.08
A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol (1997) 1.08
Control of T cell development in vivo by subdomains within the IL-7 receptor alpha-chain cytoplasmic tail. J Immunol (2001) 1.08
CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol (1999) 1.08
Surface properties and functional characteristics of infiltrating cells harvested from acutely rejecting cardiac allografts in inbred rats. Transplantation (1975) 1.08
Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol (1993) 1.07
Cholinergic augmentation of lymphocyte-mediated cytotoxicity. A study of the cholinergic receptor of cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1974) 1.07
Proliferation of T lymphocytes in response to interleukin 2 varies with their state of activation. J Immunol (1986) 1.07
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant (2011) 1.05
On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses. J Immunol (1998) 1.05
Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts. J Immunol (1993) 1.05
Microtubule function in immune and nonimmune lymphocyte-mediated cytotoxicity. Science (1973) 1.05